Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of ispinesib in treating young
patients with relapsed or refractory solid tumors or lymphoma. Drugs used in chemotherapy,
such as ispinesib, work in different ways to stop the growth of cancer cells, either by
killing the cells or by stopping them from dividing